Diversity within the pRb pathway: Is there a code of conduct

Oncogene

Volumn 31, Issue 40, 2012, Pages 4343-4352

  Munro, S ^a   Carr, S M ^a   La Thangue, N B ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

acetylation; E2F 1; methylation; phosphorylation; pRb

Indexed keywords

RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F1;

ACETYLATION; CANCER INHIBITION; CELL CYCLE REGULATION; PRIORITY JOURNAL; PROTEIN METHYLATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REVIEW; UBIQUITINATION;

ACETYLATION; APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; E2F1 TRANSCRIPTION FACTOR; HUMANS; METHYLATION; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RETINOBLASTOMA PROTEIN; SIGNAL TRANSDUCTION; UBIQUITINATION;

EID: 84867229626     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.603     Document Type: Review

References (94)

1. Adams PD. (2001). Regulation of the retinoblastoma tumor suppressor protein by cyclin/cdks. Biochim Biophys Acta 1471: M123-M133.
2. Adams PD, Li X, Sellers WR, Baker KB, Leng X, Harper JW et al. (1999). Retinoblastoma protein contains a C-terminal motif that targets it for phosphorylation by cyclin-cdk complexes. Mol Cell Biol 19: 1068-1080.
3. Bedford MT, Clarke SG. (2009). Protein arginine methylation in mammals: who, what, and why. Mol Cell 33: 1-13.
4. Blattner C, Sparks A, Lane D. (1999). Transcription factor E2F-1 is upregulated in response to DNA damage in a manner analogous to that of p53. Mol Cell Biol 19: 3704-3713.
5. Bonasio R, Lecona E, Reinberg D. (2010). MBT domain proteins in development and disease. Semin Cell Dev Biol 21: 221-230.
6. Brown MA, Sims 3rd RJ, Gottlieb PD, Tucker PW. (2006). Identification and characterization of Smyd2: a split SET/MYND domain-containing histone H3 lysine 36-specific methyltransferase that interacts with the Sin3 histone deacetylase complex. Mol Cancer 5: 26.
7. Campanero MR, Flemington EK. (1997). Regulation of E2F through ubiquitin-proteasome-dependent degradation: stabilization by the pRB tumor suppressor protein. Proc Natl Acad Sci USA 94: 2221-2226.
8. Carr SM, Munro S, Kessler B, Oppermann U, La Thangue NB. (2011). Interplay between lysine methylation and Cdk phosphorylation in growth control by the retinoblastoma protein. EMBO J 30: 317-327.
9. Chan HM, Krstic-Demonacos M, Smith L, Demonacos C, La Thangue NB. (2001a). Acetylation control of the retinoblastoma tumour-suppressor protein. Nat Cell Biol 3: 667-674.
10. Chan HM, Smith L, La Thangue NB. (2001b). Role of LXCXE motifdependent interactions in the activity of the retinoblastoma protein. Oncogene 20: 6152-6163.
11. Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC et al. (2009). Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325: 834-840.
12. Clarke AR, Maandag ER, van Roon M, van der Lugt NM, van der Valk M, Hooper ML et al. (1992). Requirement for a functional Rb-1 gene in murine development. Nature 359: 328-330.
13. Classon M, Harlow E. (2002). The retinoblastoma tumour suppressor in development and cancer. Nat Rev Cancer 2: 910-917.
14. Cobrinik D. (2005). Pocket proteins and cell cycle control. Oncogene 24: 2796-2809.
15. Connell-Crowley L, Harper JW, Goodrich DW. (1997). Cyclin D1/Cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation. Mol Biol Cell 8: 287-301.
16. Dai C, Gu W. (2010). p53 post-translational modification: deregulated in tumorigenesis. Trends Mol Med 16: 528-536.
17. Delston RB, Matatall KA, Sun Y, Onken MD, Harbour JW. (2011). p38 phosphorylates Rb on Ser567 by a novel, cell cycle-independent mechanism that triggers Rb-Hdm2 interaction and apoptosis. Oncogene 30: 588-599.
18. Dick FA, Dyson N. (2003). pRB contains an E2F1-specific binding domain that allows E2F1-induced apoptosis to be regulated separately from other E2F activities. Mol Cell 12: 639-649.
19. Dyson N. (1998). The regulation of E2F by pRB-family proteins. Genes Dev 12: 2245-2262.
20. Fagan R, Flint KJ, Jones N. (1994). Phosphorylation of E2F-1 modulates its interaction with the retinoblastoma gene product and the adenoviral E4 19 kDa protein. Cell 78: 799-811.
21. Fang Y, Nicholl MB. (2011). Sirtuin 1 in malignant transformation: friend or foe? Cancer Lett 306: 10-14.
22. Fischle W, Wang Y, Allis CD. (2003). Binary switches and modification cassettes in histone biology and beyond. Nature 425: 475-479.
23. Gonzalo S, Garcia-Cao M, Fraga MF, Schotta G, Peters AH, Cotter SE et al. (2005). Role of the RB1 family in stabilizing histone methylation at constitutive heterochromatin. Nat Cell Biol 7: 420-428.
24. Gorges LL, Lents NH, Baldassare JJ. (2008). The extreme COOH terminus of the retinoblastoma tumor suppressor protein pRb is required for phosphorylation on Thr-373 and activation of E2F. Am J Physiol Cell Physiol 295: C1151-C1160.
25. Gu W, Schneider JW, Condorelli G, Kaushal S, Mahdavi V, Nadal-Ginard B. (1993). Interaction of myogenic factors and the retinoblastoma protein mediates muscle cell commitment and differentiation. Cell 72: 309-324.
26. Harbour JW, Dean DC. (2000). The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev 14: 2393-2409.
27. Harbour JW, Luo RX, Dei Santi A, Postigo AA, Dean DC. (1999). Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell 98: 859-869.
28. Hediger F, Gasser SM. (2006). Heterochromatin protein 1: don't judge the book by its cover!. Curr Opin Genet Dev 16: 143-150.
29. Herrera RE, Chen F, Weinberg RA. (1996). Increased histone H1 phosphorylation and relaxed chromatin structure in Rb-deficient fibroblasts. Proc Natl Acad Sci USA 93: 11510-11515.
30. Hirschi A, Cecchini M, Steinhardt RC, Schamber MR, Dick FA, Rubin SM. (2010). An overlapping kinase and phosphatase docking site regulates activity of the retinoblastoma protein. Nat Struct Mol Biol 17: 1051-1057.
31. Inoue Y, Kitagawa M, Taya Y. (2007). Phosphorylation of pRB at Ser612 by Chk1/2 leads to a complex between pRB and E2F-1 after DNA damage. EMBO J 26: 2083-2093.
32. Ivanova IA, Nakrieko KA, Dagnino L. (2009). Phosphorylation by p38 MAP kinase is required for E2F1 degradation and keratinocyte differentiation. Oncogene 28: 52-62.
33. Jacks T, Fazeli A, Schmitt EM, Bronson RT, Goodell MA, Weinberg RA. (1992). Effects of an Rb mutation in the mouse. Nature 359: 295-300.
34. Jackson PK, Eldridge AG. (2002). The SCF ubiquitin ligase: an extended look. Mol Cell 9: 923-925.
35. Jenuwein T, Allis CD. (2001). Translating the histone code. Science 293: 1074-1080.
36. Khidr L, Chen PL. (2006). RB, the conductor that orchestrates life, death and differentiation. Oncogene 25: 5210-5219.
37. Knudsen ES, Wang JY. (1996). Differential regulation of retinoblastoma protein function by specific Cdk phosphorylation sites. J Biol Chem 271: 8313-8320.
38. Knudsen KE, Booth D, Naderi S, Sever-Chroneos Z, Fribourg AF, Hunton IC et al. (2000). RB-dependent S-phase response to DNA damage. Mol Cell Biol 20: 7751-7763.
39. Kontaki H, Talianidis I. (2010). Lysine methylation regulates E2F1-induced cell death. Mol Cell 39: 152-160.
40. Ledl A, Schmidt D, Muller S. (2005). Viral oncoproteins E1A and E7 and cellular LxCxE proteins repress SUMO modification of the retinoblastoma tumor suppressor. Oncogene 24: 3810-3818.
41. Leduc C, Claverie P, Eymin B, Col E, Khochbin S, Brambilla E et al. (2006). p14ARF promotes RB accumulation through inhibition of its Tip60-dependent acetylation. Oncogene 25: 4147-4154.
42. Lents NH, Gorges LL, Baldassare JJ. (2006). Reverse mutational analysis reveals threonine-373 as a potentially sufficient phosphorylation site for inactivation of the retinoblastoma tumor suppressor protein (pRB). Cell Cycle 5: 1699-1707.
43. Lin WC, Lin FT, Nevins JR. (2001). Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation. Genes Dev 15: 1833-1844.
44. Liu K, Lin FT, Ruppert JM, Lin WC. (2003). Regulation of E2F1 by BRCT domain-containing protein TopBP1. Mol Cell Biol 23: 3287-3304.
45. Liu K, Luo Y, Lin FT, Lin WC. (2004). TopBP1 recruits Brg1/Brm to repress E2F1-induced apoptosis, a novel pRb-independent and E2F1-specific control for cell survival. Genes Dev 18: 673-686.
46. Longworth MS, Dyson NJ. (2010). pRb, a local chromatin organizer with global possibilities. Chromosoma 119: 1-11.
47. Lowe ED, Tews I, Cheng KY, Brown NR, Gul S, Noble ME et al. (2002). Specificity determinants of recruitment peptides bound to phospho-CDK2/cyclin A. Biochemistry 41: 15625-15634.
48. Ludlow JW, Glendening CL, Livingston DM, DeCarprio JA. (1993). Specific enzymatic dephosphorylation of the retinoblastoma protein. Mol Cell Biol 13: 367-372.
49. MacLellan WR, Xiao G, Abdellatif M, Schneider MD. (2000). A novel Rb-and p300-binding protein inhibits transactivation by MyoD. Mol Cell Biol 20: 8903-8915.
50. Markham D, Munro S, Soloway J, O'Connor DP, La Thangue NB. (2006). DNA-damage-responsive acetylation of pRb regulates binding to E2F-1. EMBO Rep 7: 192-198.
51. Martelli F, Hamilton T, Silver DP, Sharpless NE, Bardeesy N, Rokas M et al. (2001). p19ARF targets certain E2F species for degradation. Proc Natl Acad Sci USA 98: 4455-4460.
52. Marti A, Wirbelauer C, Scheffner M, Krek W. (1999). Interaction between ubiquitin-protein ligase SCFSKP2 and E2F-1 underlies the regulation of E2F-1 degradation. Nat Cell Biol 1: 14-19.
53. Martin C, Zhang Y. (2005). The diverse functions of histone lysine methylation. Nat Rev Mol Cell Biol 6: 838-849.
54. Martinez-Balbas MA, Bauer UM, Nielsen SJ, Brehm A, Kouzarides T. (2000). Regulation of E2F1 activity by acetylation. EMBO J 19: 662-671.
55. Marzio G, Wagener C, Gutierrez MI, Cartwright P, Helin K, Giacca M. (2000). E2F family members are differentially regulated by reversible acetylation. J Biol Chem 275: 10887-10892.
56. Meek DW, Anderson CW. (2009). Posttranslational modification of p53: cooperative integrators of function. Cold Spring Harb Perspect Biol 1: a000950.
57. Min J, Allali-Hassani A, Nady N, Qi C, Ouyang H, Liu Y et al. (2007). L3MBTL1 recognition of mono-and dimethylated histones. Nat Struct Mol Biol 14: 1229-1230.
58. Mittnacht S. (1998). Control of pRB phosphorylation. Curr Opin Genet Dev 8: 21-27.
59. Miyake S, Sellers WR, Safran M, Li X, Zhao W, Grossman SR et al. (2000). Cells degrade a novel inhibitor of differentiation with E1A-like properties upon exiting the cell cycle. Mol Cell Biol 20: 8889-8902.
60. Muller S, Hoege C, Pyrowolakis G, Jentsch S. (2001). SUMO, ubiquitin's mysterious cousin. Nat Rev Mol Cell Biol 2: 202-210.
61. Muller S, Ledl A, Schmidt D. (2004). SUMO: a regulator of gene expression and genome integrity. Oncogene 23: 1998-2008.
62. Munro S, Khaire N, Inche A, Carr S, La Thangue NB. (2010). Lysine methylation regulates the pRb tumour suppressor protein. Oncogene 29: 2357-2367.
63. Nath N, Wang S, Betts V, Knudsen E, Chellappan S. (2003). Apoptotic and mitogenic stimuli inactivate Rb by differential utilization of p38 and cyclin-dependent kinases. Oncogene 22: 5986-5994.
64. Nguyen DX, Baglia LA, Huang SM, Baker CM, McCance DJ. (2004). Acetylation regulates the differentiation-specific functions of the retinoblastoma protein. EMBO J 23: 1609-1618.
65. Pediconi N, Ianari A, Costanzo A, Belloni L, Gallo R, Cimino L et al. (2003). Differential regulation of E2F1 apoptotic target genes in response to DNA damage. Nat Cell Biol 5: 552-558.
66. Pickard A, Wong PP, McCance DJ. (2010). Acetylation of Rb by PCAF is required for nuclear localization and keratinocyte differentiation. J Cell Sci 123: 3718-3726.
67. Pickart CM, Eddins MJ. (2004). Ubiquitin: structures, functions, mechanisms. Biochim Biophys Acta 1695: 55-72.
68. Polager S, Ginsberg D. (2008). E2F-at the crossroads of life and death. Trends Cell Biol 18: 528-535.
69. Puri PL, Sartorelli V, Yang XJ, Hamamori Y, Ogryzko VV, Howard BH et al. (1997). Differential roles of p300 and PCAF acetyltransferases in muscle differentiation. Mol Cell 1: 35-45.
70. Rubin SM, Gall AL, Zheng N, Pavletich NP. (2005). Structure of the Rb C-terminal domain bound to E2F1-DP1: a mechanism for phosphorylation-induced E2F release. Cell 123: 1093-1106.
71. Saddic LA, West LE, Aslanian A, Yates 3rd JR, Rubin SM, Gozani O et al. (2010). Methylation of the retinoblastoma tumor suppressor by SMYD2. J Biol Chem 285: 37733-37740.
72. Sahin F, Sladek TL. (2010). E2F-1 binding affinity for pRb is not the only determinant of the E2F-1 activity. Int J Biol Sci 6: 382-395.
73. Schulman BA, Lindstrom DL, Harlow E. (1998). Substrate recruitment to cyclin-dependent kinase 2 by a multipurpose docking site on cyclin A. Proc Natl Acad Sci USA 95: 10453-10458.
74. Sherr CJ. (2000). The Pezcoller lecture: cancer cell cycles revisited. Cancer Res 60: 3689-3695.
75. Sherr CJ, Roberts JM. (2004). Living with or without cyclins and cyclin-dependent kinases. Genes Dev 18: 2699-2711.
76. Sims 3rd RJ, Reinberg D. (2008). Is there a code embedded in proteins that is based on post-translational modifications? Nat Rev Mol Cell Biol 9: 815-820.
77. Stevens C, La Thangue NB. (2003). E2F and cell cycle control: a double-edged sword. Arch Biochem Biophys 412: 157-169.
78. Stevens C, Smith L, La Thangue NB. (2003). Chk2 activates E2F-1 in response to DNA damage. Nat Cell Biol 5: 401-409.
79. Templeton DJ, Park SH, Lanier L, Weinberg RA. (1991). Nonfunctional mutants of the retinoblastoma protein are characterized by defects in phosphorylation, viral oncoprotein association, and nuclear tethering. Proc Natl Acad Sci USA 88: 3033-3037.
80. Trimarchi JM, Lees JA. (2002). Sibling rivalry in the E2F family. Nat Rev Mol Cell Biol 3: 11-20.
81. Trouche D, Cook A, Kouzarides T. (1996). The CBP co-activator stimulates E2F1/DP1 activity. Nucleic Acids Res 24: 4139-4145.
82. Uchida C, Miwa S, Kitagawa K, Hattori T, Isobe T, Otani S et al. (2005). Enhanced Mdm2 activity inhibits pRB function via ubiquitin-dependent degradation. EMBO J 24: 160-169.
83. Wang B, Liu K, Lin FT, Lin WC. (2004). A role for 14-3-3 tau in E2F1 stabilization and DNA damage-induced apoptosis. J Biol Chem 279: 54140-54152.
84. Wang S, Nath N, Minden A, Chellappan S. (1999). Regulation of Rb and E2F by signal transduction cascades: divergent effects of JNK1 and p38 kinases. EMBO J 18: 1559-1570.
85. Weinberg RA. (1995). The retinoblastoma protein and cell cycle control. Cell 81: 323-330.
86. Wilkinson KA, Henley JM. (2010). Mechanisms, regulation and consequences of protein SUMOylation. Biochem J 428: 133-145.
87. Wong S, Weber JD. (2007). Deacetylation of the retinoblastoma tumour suppressor protein by SIRT1. Biochem J 407: 451-460.
88. Xiao ZX, Chen J, Levine AJ, Modjtahedi N, Xing J, Sellers WR et al. (1995). Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 375: 694-698.
89. Xu M, Sheppard KA, Peng CY, Yee AS, Piwnica-Worms H. (1994). Cyclin A/CDK2 binds directly to E2F-1 and inhibits the DNAbinding activity of E2F-1/DP-1 by phosphorylation. Mol Cell Biol 14: 8420-8431.
90. Yang XJ. (2004). Lysine acetylation and the bromodomain: a new partnership for signaling. Bioessays 26: 1076-1087.
91. Yeste-Velasco M, Folch J, Pallas M, Camins A. (2009). The p38(MAPK) signaling pathway regulates neuronal apoptosis through the phosphorylation of the retinoblastoma protein. Neurochem Int 54: 99-105.
92. Zarkowska T, Mittnacht S. (1997). Differential phosphorylation of the retinoblastoma protein by G1/S cyclin-dependent kinases. J Biol Chem 272: 12738-12746.
93. Zhang Y, Reinberg D. (2001). Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. Genes Dev 15: 2343-2360.
94. Zhang Z, Wang H, Li M, Rayburn ER, Agrawal S, Zhang R. (2005). Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway. Oncogene 24: 7238-7247.